Harmony Biosciences Holdings, Inc. HRMY
Institutional shares held
44 Million
68.4K
calls
52.1K
puts
Total value of holdings
$1.29B
$2.01M
calls
$1.53M
puts
Market Cap
$1.74B
59,161,400
Shares Out.
Institutional ownership
74.33%
# of Institutions
213
We take great care to ensure that the data presented and summarized in this overview for Harmony Biosciences Holdings, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding HRMY
View all-
Valor Management LLC Chicago, IL11.2MShares$330 Million100.0% of portfolio
-
Black Rock Inc. New York, NY5.92MShares$174 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.63MShares$107 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA2.61MShares$76.6 Million11.71% of portfolio
-
Pacer Advisors, Inc. Malvern, PA2.49MShares$73.4 Million0.22% of portfolio
-
State Street Corp Boston, MA1.3MShares$38.1 Million0.0% of portfolio
-
Ven Bio Partners LLC San Francisco, CA1.04MShares$30.4 Million13.59% of portfolio
-
Morgan Stanley New York, NY885KShares$26 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX845KShares$24.8 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA754KShares$22.2 Million0.0% of portfolio
Latest Institutional Activity in HRMY
Top Purchases
Top Sells
About HRMY
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
Insider Transactions at HRMY
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 29
2024
|
Sandip Kapadia CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
8,013
-53.42%
|
$264,429
$33.58 P/Share
|
|
Mar 29
2024
|
Sandip Kapadia CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
-
|
|
Mar 15
2024
|
Jeffrey Dierks CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
11,979
-100.0%
|
$383,328
$32.0 P/Share
|
|
Mar 15
2024
|
Jeffrey Dierks CHIEF COMMERCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
11,979
+50.0%
|
$95,832
$8.22 P/Share
|
|
Mar 08
2024
|
Jeffrey Dierks CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
194
-100.0%
|
$6,208
$32.0 P/Share
|
|
Mar 08
2024
|
Jeffrey Dierks CHIEF COMMERCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
194
+50.0%
|
$1,552
$8.22 P/Share
|
|
Mar 29
2023
|
Sandip Kapadia CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
15,414
-51.38%
|
$508,662
$33.36 P/Share
|
|
Mar 29
2023
|
Sandip Kapadia CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+50.0%
|
-
|
|
Dec 14
2022
|
Jack Nielsen |
SELL
Open market or private sale
|
Indirect |
2,834
-0.11%
|
$167,206
$59.96 P/Share
|
|
Dec 14
2022
|
Andreas Wicki Director |
SELL
Open market or private sale
|
Indirect |
130
-0.01%
|
$7,800
$60.0 P/Share
|
|
Dec 13
2022
|
Andreas Wicki Director |
SELL
Open market or private sale
|
Indirect |
6,320
-0.29%
|
$379,200
$60.13 P/Share
|
|
Dec 12
2022
|
Andreas Wicki Director |
SELL
Open market or private sale
|
Indirect |
22,391
-1.03%
|
$1,343,460
$60.36 P/Share
|
|
Dec 09
2022
|
Jack Nielsen |
SELL
Open market or private sale
|
Indirect |
9,847
-0.38%
|
$580,973
$59.89 P/Share
|
|
Dec 08
2022
|
Jack Nielsen |
SELL
Open market or private sale
|
Indirect |
36,878
-1.41%
|
$2,175,802
$59.9 P/Share
|
|
Dec 07
2022
|
Jack Nielsen |
SELL
Open market or private sale
|
Indirect |
64,026
-2.38%
|
$3,841,560
$60.35 P/Share
|
|
Dec 05
2022
|
Andreas Wicki Director |
SELL
Open market or private sale
|
Indirect |
77,853
-3.45%
|
$4,749,033
$61.23 P/Share
|
|
Dec 02
2022
|
Andrew Serafin CHIEF STRATEGY OFFICER |
SELL
Open market or private sale
|
Direct |
38,000
-98.79%
|
$2,280,000
$60.41 P/Share
|
|
Dec 02
2022
|
Andrew Serafin CHIEF STRATEGY OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
38,000
+50.0%
|
$304,000
$8.22 P/Share
|
|
Dec 01
2022
|
Jack Nielsen |
SELL
Open market or private sale
|
Indirect |
65,652
-2.39%
|
$3,939,120
$60.0 P/Share
|
|
Nov 30
2022
|
Jack Nielsen |
SELL
Open market or private sale
|
Indirect |
42,667
-1.53%
|
$2,474,686
$58.93 P/Share
|
Last 12 Months Summary
Buy / Acquisition
27.2K
Shares
From
2
Insiders
| Exercise of conversion of derivative security | 27.2K shares |
|---|
Sell / Disposition
20.2K
Shares
From
2
Insiders
| Open market or private sale | 12.2K shares |
|---|---|
| Payment of exercise price or tax liability | 8.01K shares |